DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The "2018 Angina Pectoris Or Ischemic Chest Pain Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Angina Pectoris Or Ischemic Chest Pain Market" report has been added to ResearchAndMarkets.com's offering.

Angina or Angina Pectoris market is estimated to be valued around $12 billion. It occurs when the blood flowing into coronary arteries fails to provide the required oxygen volumes. The main cause of this condition is Coronary heart disease. Unlike heart attack, Angina is temporary and does not cause any damage to the heart muscles. It is often classified as stable Angina and unstable Angina.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Angina Pectoris Or Ischemic Chest Pain pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Angina Pectoris Or Ischemic Chest Pain pipeline product. Mechanism of Action and the target area of the pipeline product are also provided.

In addition to complete details of each product, the report provides key trends in Angina Pectoris Or Ischemic Chest Pain pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

Angionetics Inc Beijing CoSci Med-Tech Co.,Ltd Caladrius Biosciences Inc G. Pohl-Boskamp GmbH & Co KG Hemostemix Inc ID Pharma Co Ltd Juventas Therapeutics Inc Kuhnil Pharmaceutical Co Ltd Sanofi S.A. TSH Biopharm Corporation Ltd ViroMed Co Ltd XyloCor Therapeutics, Inc.

Key Topics Covered:

1 Table of Contents

2 Angina Pectoris Or Ischemic Chest Pain Pipeline Analysis

3 Angina Pectoris Or Ischemic Chest Pain- Company Wise Pipeline Analysis

4 Angina Pectoris Or Ischemic Chest Pain R&D Pipeline Snapshots

5 Recent Developments in Angina Pectoris Or Ischemic Chest Pain Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/3kb9z7/angina_pectoris?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005339/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Analgesics,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 07:23 AM/DISC: 07/30/2018 07:23 AM

http://www.businesswire.com/news/home/20180730005339/en